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Whole-brain radiation therapy (WBRT) remains standard
practice for cerebral metastases, either as monotherapy or
in conjunction with surgery or stereotactic radiosurgery
(SRS).1 Although potential radiation-induced side effects
after WBRT are well described, we report the ﬁrst (to our
knowledge) case of fatal leukoencephalopathy following
WBRT and SRS boost.Case
The patient was, at time of initial diagnosis, a 63-year-
old woman with a right lower lobe lung mass inciden-
tally detected during workup for persistent back pain.
Medical history was notable only for well-managedConﬂicts of interest: None.
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Subsequent workup disclosed 2 synchronous lung
primaries: a ride-sided pT1N1 adenocarcinoma and a
left-sided pT2aN0 adenocarcinoma, each treated with
surgical resection and lymph node sampling. The
morphologic subtypes suggested 2 primary cancers
versus metastatic disease. She received 1 cycle of full-
dose cisplatin/vinorelbine, with further planned cycles
aborted because of poor tolerance and functional decline.
Approximately 1.5 years after chemotherapy, she
developed headaches and right-sided ataxia. Magnetic
resonance imaging (MRI) disclosed 5 lesions, with the
largest in the left frontal (2.3  2.6 cm), right frontal
(1.8  2.0 cm), and right parietal (1.7  1.6 cm) regions.
There had been no prior brain imaging; positron emission
tomography imaging did not reveal active extracranial
disease. Steroids were initiated, after which WBRT (30
Gy/10 fractions) was completed. Because of recurrent
headache, she remained on 10 mg dexamethasone daily.
One month post-WBRT, the 3 bulkier lesions were
treated with frameless, linear acceleratorebased SRS;
each lesion received 15.5 Gy to isocenter and 13 Gy to
the periphery (Fig 1).of the American Society for Radiation Oncology. This is an open access
by-nc-nd/4.0/).
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of the previously mentioned issues, she developed fatigue,
anorexia, failure to thrive, and persistent but minor mental
status changes, notable for decreased interactivity.
Steadily, her neurocognitive decline progressed with
worsening fatigue, inattention, inactivity, decreased
personal interactivity, and poor oral intake in the absence
of headaches or focal neurologic deﬁcits. Eventually she
slept the majority of the day, although she remained
arouseable and appropriate in actions and communication
during wakeful periods, which continued to diminish in
frequency and duration. Magnetic resonance imaging
(2 weeks before death) showed regression of the SRS-
targeted lesions and decreased perilesional edema;
2 infratentorial lesions (not boosted with SRS) were no
longer visualized. There was interval development of
cerebral and cerebellar volume loss, with new bilateral
deep and periventricular white matter changes (Fig 2).
Additional diagnostic testing, including urine and blood
cultures, syphilis screening, blood counts, and metabolic
panels, were unremarkable. An electroencephalogram
showed diffuse background slowing consistent with
moderate to severe encephalopathy with no focal or
epileptiform abnormalities. Lumbar puncture was not
performed. The patient died (2 months after SRS, 3
months after WBRT) under a comfort care approach, with
punctate episodes of consciousness prior. Autopsy was
declined by her family.Discussion
Radiation-induced leukoencephalopathy is a well-
described late sequelae deﬁned clinically by variable
neurocognitive changes and radiologically by deep andFigure 1 Contrast-enhanced T1-weighted magnetic resonance imag
radiosurgery planning.periventricular white matter hyperintensities on
T2-weighted MRI series in the absence of focal lesions.2
The incidence of leukoencephalopathy is unclear.
A retrospective series reported grade 1-3 leukoence-
phalopathy in 34% of patients 6 months after 40 Gy/20
fractions, with increasing incidence at longer follow-up.3
A series of 94 patients examining late effects after
prophylactic cranial irradiation reported periventricular
and subcortical lesions on computed tomography (CT)
scan consistent with white matter changes in 82% of
patients; neuropsychologic impairment scores correlated
with the extent of these lesions (r Z 0.7, P < .05),
although the number evaluated for assessment was low
(nZ 12) and no standardized grading system was used.4
In a prospective study of 92 patients receiving WBRT
with regular CT or MRI assessments, brain atrophy
developed in 30%, though it did not correlate with
changes on the Mini-Mental Status Exam (MMSE); the
authors did not report white matter changes.5 In a series
of 44 melanoma patients undergoing WBRT to 20 Gy/5
fractions (n Z 21) or 30 Gy/10 fractions (n Z 16), the
incidence of leukoencephalopathy seen on MRI was
5.4%.6
The incidence of leukoencephalopathy with SRS plus
WBRT is similarly unclear. A Japanese prospective
study comparing SRS (n Z 67) alone with WBRT and
SRS (n Z 65) reported leukoencephalopathy in 9
patients, 7 in the combined modality group and 2 after
SRS alone.7 A retrospective single-institution series
speciﬁcally evaluating leukoencephalopathy in patients
treated with WBRT alone versus WBRT and SRS
reported a signiﬁcantly higher rate in patients at 1 year
after undergoing combination therapy using an
investigator-derived grading system (13 vs 92%).
Notably, the combination group had greater likelihood ofes 1 month after whole-brain radiation therapy for stereotactic
Figure 2 Magnetic resonance images during patient’s ﬁnal hospitalization. Axial T1-weighted postcontrast images showing
regression of treated lesions (top). Axial T2-weighted ﬂuid attenuated inversion recovery images showing diffuse subcortical white
matter hyperintensities (bottom).
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received more SRS treatments.8 A retrospective series
examining 103 patients who had undergone at least 2
courses of radiosurgery found that both WBRT and a
higher integral dose were associated with an increased
likelihood of developing leukoencephalopathy on MRI.9
These series suggest SRS after WBRT can exacerbate
leukoencephalopathy, possibly as a simple function of
dose. Hypothetically, SRS may trigger an immune or
inﬂammatory reaction that precipitates demyelinating
changes “primed” after WBRT in a uniquely susceptible
patient; however, to our knowledge, such an effect has
not been described.
The relationship between white matter changes and
severity of clinical symptoms is unclear. An early retro-
spective series reported a correlation between severe
white matter changes on MRI and clinical symptoms,
though also reporting leukoencephalopathic symptoms inpatients with mild radiologic changes.10 A secondary
analysis of Radiation Therapy Oncology Group 9104
(a randomized study of WBRT with or without motexaﬁn
gadolinium) investigated neurocognitive impairment after
WBRT. The authors showed that larger lesion volume
and poorer response to therapy were signiﬁcant predictors
of worse neurocognitive impairment.11 In a planned
secondary analysis of the previously mentioned Japanese
randomized trial, neurocognitive function was evaluated
by MMSE (n Z 92); of 7 patients with leukoencephal-
opathy (all SRS þ WBRT patients), 4 had a signiﬁcant
drop from their baseline MMSE. This represented a small
number of the overall study population who had an
observed MMSE decline. Although similar MMSE
declines were observed in both cohorts, the WBRT
þ SRS group experienced a longer median time to
deterioration (12 vs 6.6 months) and the decline was
attributed to therapy in 5 patients (40%), whereas in the
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attributed to recurrent disease.12 Taken together, these
reports suggest that leukoencephalopathy can cause
variable clinical effects that are difﬁcult to predict or
quantify.
There are clinical data indicating that combination
therapy can lead to worse neurocognitive outcomes.
A randomized trial from MD Anderson Cancer Center
evaluating SRS alone compared with SRS with WBRT in
58 patients with 1 to 3 brain metastases with prospective
neurocognitive assessments was terminated after an
interim analysis showed decreased short-term memory at
4 months, which was the study’s primary endpoint.13 The
Alliance/NCCTG N0574 randomized trial of 208 patients
with 1 to 3 brain metastases reported declines in delayed
recall, immediate recall, and verbal ﬂuency after WBRT
þ SRS versus SRS alone.14 Notably, both studies showed
intracranial control was superior with combination ther-
apy, though no effect on overall survival was observed.
Leukoencephalopathic changes were not speciﬁcally
reported in these studies.
It is possible that fatal leukoencephalopathic events after
WBRT SRS in the past that were either not recognized as
toxicities or not deemed worthy of reporting in peer-
reviewed literature; however, with decades of experience
using similar biologically equivalent doses in routine
practice, it is unlikely that similar events would go unre-
ported. In the reported case, there was no clear etiologic
process that could otherwise explain the neurocognitive
changes observed. Whether leukoencephalopathy was the
only pathology involved cannot be deﬁnitively stated
without autopsy conﬁrmation, but the severity of neuro-
cognitive changes in proximity to therapy in conjunction
with characteristic MRI changes strongly suggest a severe
reaction in this patient.
In summary, clinicians should be aware of potential
severe radiation-induced leukoencephalopathy after
combination WBRT and SRS, which manifested as a fatal
complication in our patient with bulky brain metastases.
We do not advocate changing clinical practice based upon
a case report. Even after our experience with this patient,
we would treat another steroid-dependent brain metastasis
patient similarly, because WBRT can best address acutely
symptomatic intracranial disease with SRS providing
more durable intracranial control. Although the utility, in
terms of survival and quality of life, of WBRT in non-
small cell lung cancer patients who were ineligible for
SRS has been called into question since the results from
the UK Medical Research Council QUARTZ (Quality of
Life after Treatment of Brain Metastases) randomized trial
were reported,15 more data are needed to best address
which patients would beneﬁt from withholding radiation
therapy. Nevertheless, we advocate against routine use of
WBRT in patients with limited brain metastases, asrecommended by the American Society of Radiation
Oncology’s Choosing Wisely campaign (http://www.
choosingwisely.org/astro-releases-second-list/).References
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